-
公开(公告)号:US20210324035A1
公开(公告)日:2021-10-21
申请号:US17273192
申请日:2019-09-04
申请人: The Regents of the University of California , California Institute of Technology , The Olivia Newton-John Cancer Research Institute
发明人: Owen N. Witte , Jami McLaughlin Witte , Antoni Ribas , Lili Yang , Michael T. Bethune , Jonathan Cebon , Katherine Woods , Ashley J. Knights , David Baltimore
IPC分类号: C07K14/725 , A61K35/17 , C12N15/86 , C12N5/0783 , A61P35/00
摘要: Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.